Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
Keytruda works by harnessing the power of the body’s immune system to attack cancer cells. ... There can be side effects. Immunotherapy can kick the immune system into overdrive, causing a ...
The role of keytruda in the intention-to-treat population remains uncertain at this time. In the U.S., Lynparza has three approved indications in ovarian cancer. Keytruda is not approved to treat ...
Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...
Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a ...
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.
The company has been seeking to test Keytruda in combination with other treatments and expand its use in types of cancers not yet treated by immunotherapies, as the drug faces loss of patent ...
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed